findmyKOL
Clinical trialNCT07082439RecruitingPhase 2Interventional

Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma

SponsorAbramson Cancer Center at Penn MedicineEnrollment27Colorectal Adenocarcinoma Metastatic in the Liver
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Abramson Cancer Center at the University of Pennsylvania

    Philadelphia, Pennsylvania, United States

    William Chapin, MD, MSCE
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
10 Sept 2025
Primary completion
30 Sept 2027
Completion
30 Sept 2029
Last update posted
22 Sept 2025
Registered enrollment
27
Registry id
NCT07082439
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.